NervGen Pharma Corp.

NervGen Pharma Corp. is a biotechnology company focused on discovering, developing, and commercializing pharmaceutical treatments for nervous system repair in neurotrauma and neurologic disease. Its lead candidate, NVG-291, is in a Phase 1b/2a clinical trial for spinal cord injury (SCI), stroke, multiple sclerosis, and Alzheimer's disease. NVG-300 is in preclinical studies for ischemic stroke, amyotrophic lateral sclerosis, and a confirmatory SCI study. The company has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology for spinal cord injury and other nerve damage conditions. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.